Foundation Medicine, IMS Health Collaborate
News Jun 23, 2015
The combined offering will provide users with assessments of health outcomes and therapy effectiveness at the patient-anonymous level. IMS Health's RWE platform combines patient-anonymous claims, electronic medical record data, and biomarker data to provide health insights. Meantime, Foundation Medicine's FoundationCore is a database containing information from more than 43,000 clinical cases that have undergone testing by Foundation Medince's FoundationOne or FoundationOne Heme cancer profiling tests.
"As life sciences companies look to deploy new, targeted therapies that address the unique molecular drivers of specific cancers, it has become increasingly important for them to better understand unmet needs, treatment decisions, and outcomes for patient populations living with those cancers," Jon Resnick, IMS Health vice president and general manager of Real-World Evidence Solutions, said in a statement.
The collaboration will "drive a complete understanding of the oncology patient journey and improve clinical development and commercialization strategies," he added.
"There is recognition within the healthcare industry that rich and highly credible information will be the primary catalyst for the broad adoption of precision medicine, particularly in oncology," Michael Pellini, Foundation Medicine's CEO, said in the statement.
For scientists wrestling with problems as diverse as containing superhot plasma in a fusion reactor, improving the accuracy of weather forecasts, or probing the unexplained dynamics of a distant galaxy, turbulence-spawning shear flow is a serious complicating factor. A new supercomputer-powered effort aims to make modelling shear far easier.
18th International Conference on Pharmaceutics & Novel Drug Delivery Systems
May 27 - May 28, 2019